Juice Global Network: 2017
JUICE Global Network
322 8th Avenue
New York, NY 10001
Telephone: 212-647-1595
E-mail: [email protected]
Website: juicepharma.com
When we hear the term ‘disruptive,’ it calls to mind companies like Uber, iPhone, Netflix – all representing breakthrough innovations that have challenged the status quo while simultaneously elevating standards and expectations for customer service,” says Lynn Macrone, founding partner of the JUICE Global Network (JGN).
“It’s no different in pharma. The trend toward providing more innovative and customized solutions is reflected in the philosophy and structure of our global network.”
“When forming the JGN, we conducted research with clients already engaged with global networks to learn what was working and what was not. Many expressed frustration that their business had already been allocated to network agencies, regardless of suitability,” Macrone says. “We chose to disrupt this model, offering a more bespoke global network aligned to the specific needs of the business.”
Built from the ground up as a consortium of highly collaborative partners, executives say the JGN has been successfully launching global specialty brands since 2002. Leveraging pharma-savvy agency partnerships across the Americas, Europe, and Asia-Pacific regions, each global team is hand-selected in support of the brand it serves, and can be composed of independents as well as agencies affiliated with other networks. As a result, JGN clients who wish to continue leveraging specific agency relationships outside the network are welcome to do so.
As a member of Worldwide Partners Inc. (WPI), the JGN is able to supply the local feet on the ground needed to conduct in-country market research in support of global brand coherency infused with regional relevancy.
Executives say through the extensive WPI network, the JGN enjoys access to the resources of more than 65 independent agencies across five continents in more than 50 countries worldwide.
Acting as global brand steward, JUICE Pharma Worldwide is always at the helm of the global team, assessing the market landscape, aligning insights and strategy, and developing the global brand positioning, brand identity, and global creative campaign, executives say. At every stage of development, key client stakeholders across every region participate in the global branding process, resulting in team alignment and strategic-creative consensus. Once established, the global insight-based strategy, core creative campaign, and print and digital assets are disseminated for regional pull-through across every major market.
According to Macrone, “This commitment to establishing a bespoke collaborative team enables our network to flex and scale resources according to the changing needs of the brand. As a result, the JGN has established itself as a network that improves the client experience while creating campaigns that result in global brand recognition and commercial success.”
JUICE Pharma Worldwide and the JUICE Global Network are both WBENC-certified as women-owned business enterprises.
The Year’s Accomplishments
In 2016, JUICE Pharma Worldwide expanded its global brand roster with the addition of the global AOR assignments for multiple Shire products, including the professional and patient assignments for the global launch of Lanadelumab, a breakthrough treatment for hereditary angioedema (HAE), and the global professional assignments for both Cinryze and Firazyr, also for the treatment of HAE, a rare genetic condition.
The JGN continues its support of ongoing accounts as global HCP/digital AOR for Merck on Belsomra for insomnia, Isentress and Isentress QD for HIV-1, as well as the Merck Adult Vaccine Franchise, including Gardasil, Gardasil 9, Zostavax, and Pneumovax 23.
The JGN is engaged by Pfizer as the global HCP/HCC/digital AOR for the hemophilia brands Xyntha Solofuse and BeneFix.
Also on the global roster, the agency is assigned global market development and global launch strategy and branding in support of multiple rare disease products from Ultragenyx, including veronidase alpha for patients with mucopolysaccharidosis type VII, aceneuramic acid extended release for patients with GNE myopathy, and triheptanoin, for patients with long-chain fatty acid oxidation disorders or glucose transporter type 1 deficiency syndrome.
Structure & Services
In addition to JUICE U.S. offices in New York and San Francisco, the JGN has pharma agency partnerships in the United Kingdom, Germany, Spain, France, Italy, Denmark, Canada, Japan, China, Mexico, Brazil, and Costa Rica. Executives say the JGN provides global strategic alliances across multiple disciplines that include scientific education, multicultural, payer, public relations, and global policy.
According to agency leaders, the network also provides the opportunity for companies with more mature brands to leverage ZEST Adaptics, specializing in the global adaptation of existing content into highly effective derivative tactical execution.
Future Plans
“The JUICE Global Network is committed to delivering great client experiences all around the world,” Macrone says. “We welcome the opportunity to customize a disruptive and innovative solution in support of any global initiative dedicated to improving the lives of patients and the physicians who treat them.”
